ATC code L: Antineoplastic and immunomodulating agents
Other ATC codes

ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup L04 is part of the anatomical group L Antineoplastic and immunomodulating agents.[4]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL04.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AA03 Antilymphocyte immunoglobulin (horse)
L04AA04 Antithymocyte immunoglobulin (rabbit)
L04AA06 Mycophenolic acid
L04AA15 Alefacept
L04AA19 Gusperimus
L04AA22 Abetimus
L04AA24 Abatacept
L04AA28 Belatacept
L04AA32 Apremilast
L04AA40 Cladribine
L04AA41 Imlifidase
L04AA48 Belumosudil
L04AA58 Efgartigimod alfa

L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

L04AB01 Etanercept
L04AB02 Infliximab
L04AB03 Afelimomab
L04AB04 Adalimumab
L04AB05 Certolizumab pegol
L04AB06 Golimumab
L04AB07 Opinercept

L04AC Interleukin inhibitors

L04AC01 Daclizumab
L04AC02 Basiliximab
L04AC03 Anakinra
L04AC04 Rilonacept
L04AC05 Ustekinumab
L04AC07 Tocilizumab
L04AC08 Canakinumab
L04AC09 Briakinumab
L04AC10 Secukinumab
L04AC11 Siltuximab
L04AC12 Brodalumab
L04AC13 Ixekizumab
L04AC14 Sarilumab
L04AC15 Sirukumab
L04AC16 Guselkumab
L04AC17 Tildrakizumab
L04AC18 Risankizumab
L04AC19 Satralizumab
L04AC20 Netakimab
L04AC21 Bimekizumab
L04AC22 Spesolimab
L04AC23 Olokizumab

L04AD Calcineurin inhibitors

L04AD01 Ciclosporin
L04AD02 Tacrolimus
L04AD03 Voclosporin

L04AE Sphingosine 1-phosphate (S1P) receptor modulators

L04AE01 Fingolimod
L04AE02 Ozanimod
L04AE03 Siponimod
L04AE04 Ponesimod
L04AE05 Etrasimod

L04AF Janus-associated kinase (JAK) inhibitors

L04AF01 Tofacitinib
L04AF02 Baricitinib
L04AF03 Upadacitinib
L04AF04 Filgotinib
L04AF05 Itacitinib
L04AF06 Peficitinib
L04AF07 Deucravacitinib
L04AF08 Ritlecitinib

L04AG Monoclonal antibodies

L04AG01 Muromonab-CD3
L04AG02 Efalizumab
L04AG03 Natalizumab
L04AG04 Belimumab
L04AG05 Vedolizumab
L04AG06 Alemtuzumab
L04AG07 Begelomab
L04AG08 Ocrelizumab
L04AG09 Emapalumab
L04AG10 Inebilizumab
L04AG11 Anifrolumab
L04AG12 Ofatumumab
L04AG13 Teprotumumab
L04AG14 Ublituximab
L04AG15 Divozilimab
L04AG16 Rozanolixizumab

L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

L04AH01 Sirolimus
L04AH02 Everolimus

L04AJ Complement inhibitors

L04AJ01 Eculizumab
L04AJ02 Ravulizumab
L04AJ03 Pegcetacoplan
L04AJ04 Sutimlimab
L04AJ05 Avacopan
L04AJ06 Zilucoplan
L04AJ07 Crovalimab
L04AJ08 Iptacopan
L04AJ09 Danicopan

L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

L04AK01 Leflunomide
L04AK02 Teriflunomide

L04AX Other immunosuppressants

L04AX01 Azathioprine
L04AX02 Thalidomide
L04AX03 Methotrexate
L04AX04 Lenalidomide
L04AX05 Pirfenidone
L04AX06 Pomalidomide
L04AX07 Dimethyl fumarate
L04AX08 Darvadstrocel
L04AX09 Diroximel fumarate

References

  1. ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
  2. ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
  3. ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
  4. ^ "ATC/DDD Index 2022: code L04". WHO Collaborating Centre for Drug Statistics Methodology.
  5. ^ "ATCvet Index 2022: code QL04". WHO Collaborating Centre for Drug Statistics Methodology.
Categories